- Home
- IPA vs HLVX Comparison
IPA vs HLVX Comparison
Compare IPA & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPA
- HLVX
- Stock Information
- Founded
- IPA 1983
- HLVX 2020
- Country
- IPA United States
- HLVX United States
- Employees
- IPA N/A
- HLVX N/A
- Industry
- IPA Biotechnology: Pharmaceutical Preparations
- HLVX Biotechnology: Pharmaceutical Preparations
- Sector
- IPA Health Care
- HLVX Health Care
- Exchange
- IPA Nasdaq
- HLVX Nasdaq
- Market Cap
- IPA 98.9M
- HLVX 104.3M
- IPO Year
- IPA 2017
- HLVX 2022
- Fundamental
- Price
- IPA $2.70
- HLVX $2.06
- Analyst Decision
- IPA Strong Buy
- HLVX Hold
- Analyst Count
- IPA 2
- HLVX 1
- Target Price
- IPA $4.00
- HLVX $2.00
- AVG Volume (30 Days)
- IPA 1.7M
- HLVX 829.7K
- Earning Date
- IPA 09-15-2025
- HLVX 08-06-2025
- Dividend Yield
- IPA N/A
- HLVX N/A
- EPS Growth
- IPA N/A
- HLVX N/A
- EPS
- IPA N/A
- HLVX N/A
- Revenue
- IPA $17,744,713.00
- HLVX N/A
- Revenue This Year
- IPA $19.47
- HLVX N/A
- Revenue Next Year
- IPA $32.09
- HLVX N/A
- P/E Ratio
- IPA N/A
- HLVX N/A
- Revenue Growth
- IPA 0.01
- HLVX N/A
- 52 Week Low
- IPA $0.27
- HLVX $1.34
- 52 Week High
- IPA $2.72
- HLVX $2.17
- Technical
- Relative Strength Index (RSI)
- IPA 72.97
- HLVX 48.91
- Support Level
- IPA $1.82
- HLVX $2.07
- Resistance Level
- IPA $2.12
- HLVX $2.10
- Average True Range (ATR)
- IPA 0.20
- HLVX 0.04
- MACD
- IPA 0.03
- HLVX -0.01
- Stochastic Oscillator
- IPA 98.33
- HLVX 37.50
About IPA ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. IPA has several subsidiaries in North America and Europe.
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.